AR068552A1 - Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas - Google Patents

Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas

Info

Publication number
AR068552A1
AR068552A1 ARP080104172A ARP080104172A AR068552A1 AR 068552 A1 AR068552 A1 AR 068552A1 AR P080104172 A ARP080104172 A AR P080104172A AR P080104172 A ARP080104172 A AR P080104172A AR 068552 A1 AR068552 A1 AR 068552A1
Authority
AR
Argentina
Prior art keywords
polypeptides
phage
omegamru
cells
microbial cells
Prior art date
Application number
ARP080104172A
Other languages
English (en)
Original Assignee
Pastoral Greenhouse Gas Res Lt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pastoral Greenhouse Gas Res Lt filed Critical Pastoral Greenhouse Gas Res Lt
Publication of AR068552A1 publication Critical patent/AR068552A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/641Cysteine endopeptidases (3.4.22)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13Tumour cells, irrespective of tissue of origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/10011Details dsDNA Bacteriophages
    • C12N2795/10021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/10011Details dsDNA Bacteriophages
    • C12N2795/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/10Detection of antigens from microorganism in sample from host
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/20Reduction of greenhouse gas [GHG] emissions in agriculture, e.g. CO2
    • Y02P60/22Methane [CH4], e.g. from rice paddies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Composiciones y métodos para la administracion de moléculas inhibidoras en células microbianas, en particular, células metanogenas. Específicamente, se refiere al omegamru fago recientemente identificado, que incluye la induccion del fago, partículas del fago, y el genoma del fago, y también polipéptidos del fago, así como también polinucleotidos que codifican estos polipéptidos. También se refiere a vectores de expresion y células huésped para la produccion de estos polipéptidos, a métodos para detectar, apuntar, e inhibir células microbianas, especialmente células metanogenas, utilizando el fago revelado, polipéptidos, polinucleotidos, vectores de expresion, y células huésped, también posee composiciones farmacéuticas que comprenden el fago omegamru.
ARP080104172A 2007-09-25 2008-09-25 Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas AR068552A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97510407P 2007-09-25 2007-09-25
US98984007P 2007-11-22 2007-11-22
US98984107P 2007-11-22 2007-11-22

Publications (1)

Publication Number Publication Date
AR068552A1 true AR068552A1 (es) 2009-11-18

Family

ID=40511642

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP080104171A AR068551A1 (es) 2007-09-25 2008-09-25 Peptidos y polipeptidos permeabilizantes celulares para celulas microbianas
ARP080104173A AR068553A1 (es) 2007-09-25 2008-09-25 Vacunas y componentes de vacuna para la inhibicion de celulas microbianas
ARP080104172A AR068552A1 (es) 2007-09-25 2008-09-25 Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP080104171A AR068551A1 (es) 2007-09-25 2008-09-25 Peptidos y polipeptidos permeabilizantes celulares para celulas microbianas
ARP080104173A AR068553A1 (es) 2007-09-25 2008-09-25 Vacunas y componentes de vacuna para la inhibicion de celulas microbianas

Country Status (17)

Country Link
US (7) US8592556B2 (es)
EP (5) EP2203466B1 (es)
JP (5) JP5552053B2 (es)
CN (4) CN101918431B (es)
AR (3) AR068551A1 (es)
AU (4) AU2008304019A1 (es)
BR (5) BR122021010729B1 (es)
CA (3) CA2700162C (es)
CL (3) CL2008002859A1 (es)
DK (3) DK3327030T3 (es)
ES (3) ES2895908T3 (es)
MX (3) MX340736B (es)
NZ (1) NZ745324A (es)
RU (1) RU2528854C2 (es)
UY (3) UY31361A1 (es)
WO (3) WO2009041832A2 (es)
ZA (1) ZA201001933B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002859A1 (es) * 2007-09-25 2009-03-06 Pastoral Greenhouse Gas Res Limited Péptido señal con actividad de permeabilización de células microbianas; vector; célula huésped; molécula conjugada que lo comprende; y método para permeabilizar una célula microbiana.
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
MX2011013288A (es) * 2009-06-26 2012-02-28 Univ Leuven Kath Agentes antimicrobianos.
SG177704A1 (en) * 2009-06-26 2012-02-28 Lysando Holding Ag Antimicrobial agents
CA3169782A1 (en) * 2009-08-27 2011-03-03 Pastoral Greenhouse Gas Research Ltd Complete genome sequence of the methanogen methanobrevibacter ruminantium
JP2013532955A (ja) * 2010-04-27 2013-08-22 リサンド アクチェンゲゼルシャフト バイオフィルムの低減方法
EP4230644A3 (en) * 2012-09-19 2024-04-24 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
CN112301024A (zh) 2013-03-15 2021-02-02 通用医疗公司 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
CA2966731C (en) * 2014-11-06 2023-01-31 E. I. Du Pont De Nemours And Company Peptide-mediated delivery of rna-guided endonuclease into cells
CN104789675A (zh) * 2015-04-15 2015-07-22 江苏师范大学 一种检测荷斯坦奶牛瘤胃微生物的方法
WO2016178207A1 (en) * 2015-05-04 2016-11-10 Ramot At Tel-Aviv University Ltd. Methods and kits for fragmenting dna
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US20190292514A1 (en) * 2016-07-14 2019-09-26 Basf Se Fermentation medium comprising chelating agent
KR102551666B1 (ko) * 2016-12-29 2023-07-04 일루미나, 인코포레이티드 세포 구획 내의 생체분자에 대한 직교 접근 및 그의 태그부착을 위한 분석 시스템
US20190352609A1 (en) * 2017-01-05 2019-11-21 Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Method for preparing reticulocyte simulating particles and platelet simulating particles, and reference control
US10745439B2 (en) * 2017-03-20 2020-08-18 Regents Of The University Of Minnesota Kinase substrates and methods of use thereof
US20190233816A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
JP7334178B2 (ja) * 2018-03-19 2023-08-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド CRISPR/Cas系を使用した動物での転写モジュレーション
JP2022507487A (ja) * 2018-11-14 2022-01-18 ルーブリック・セラピューティクス・インコーポレイテッド Cd25抗体
CN109627301B (zh) * 2019-02-18 2022-08-05 浙江新银象生物工程有限公司 Nisin固体稳定剂开发及应用
CN112143747B (zh) * 2020-09-09 2022-09-13 昆明理工大学 一种噬菌体裂解酶及其基因、基因重组表达载体与应用
DK4037666T3 (da) 2020-12-08 2024-06-24 Ruminant Biotech Corp Ltd Forbedring af anordninger og fremgangsmåder til indgivelse af substanser til dyr
CN112961217B (zh) * 2021-03-19 2022-11-08 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN113121705B (zh) * 2021-04-19 2023-03-24 成都英普博集生物科技有限公司 用于制备短肽混合物的融合蛋白、目的多肽、短肽混合物的制备方法及应用
WO2024015366A1 (en) * 2022-07-11 2024-01-18 Arkea Bio Corp. Compositions and methods for reducing methane emissions in ruminant populations
WO2024097397A1 (en) * 2022-11-03 2024-05-10 Helix Nanotechnologies, Inc. Ruminal and methanogen vaccines and uses thereof
CN115938486B (zh) * 2022-12-06 2023-11-10 内蒙古农业大学 基于图神经网络的抗菌性乳酸菌株筛选方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US159861A (en) * 1875-02-16 Improvement in brooms
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
EP0150186A1 (fr) * 1983-05-03 1985-08-07 S.S.M. International Chemical Company Limited Composition a activite pharmaceutique amelioree et utilisation decelle-ci pour des usages veterinaires
GB8815968D0 (en) * 1988-07-05 1988-08-10 Pfizer Ltd Veterinary devices
JPH05219927A (ja) * 1992-02-14 1993-08-31 Gumma Pref Gov 飼料の混合装置及び混合飼料の製造方法
JP3651915B2 (ja) * 1993-06-30 2005-05-25 財団法人神奈川科学技術アカデミー シグナル配列ペプチドをコードするdna断片の探索法及びそのためのベクター
WO1995011041A1 (en) 1993-10-19 1995-04-27 Commonwealth Scientific And Industrial Research Organisation Method for improving utilisation of nutrients by ruminant or ruminant-like animals
EP0730663B1 (en) 1993-10-26 2003-09-24 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
NZ278977A (en) 1994-01-20 1997-03-24 Pastoral Agric Res Inst Nz Ltd Sustained release bolus for ruminants
EP0739198B1 (en) 1994-01-20 2003-09-17 Agresearch Limited Device for administration of beneficial materials to ruminants
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
AUPN353695A0 (en) 1995-06-14 1995-07-06 Commonwealth Scientific And Industrial Research Organisation Immunogenic preparation and method for improving the productivity of ruminant animals
US6503729B1 (en) * 1996-08-22 2003-01-07 The Board Of Trustees Of The University Of Illinois Selected polynucleotide and polypeptide sequences of the methanogenic archaeon, methanococcus jannashii
US5985907A (en) * 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
AU2002326949A1 (en) 2001-09-18 2003-05-12 The Board Of Regents Of The University Of Nebraska Method for the inhibition of methanogenesis
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US20060068386A1 (en) * 2002-03-04 2006-03-30 Alexei Slesarev Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
SE523209C2 (sv) * 2002-05-14 2004-04-06 Akzo Nobel Nv Förfarande för att reducera metanbildningen från matspjälkningsaktiviteter hos djur
EP1861490A4 (en) 2005-03-23 2010-11-17 Univ St Louis USE OF ARRAYS TO MODULATE NUTRIENT CAPTURE FUNCTIONS BY THE GASTROINTESTINAL MICROBIOTE
CL2008002859A1 (es) * 2007-09-25 2009-03-06 Pastoral Greenhouse Gas Res Limited Péptido señal con actividad de permeabilización de células microbianas; vector; célula huésped; molécula conjugada que lo comprende; y método para permeabilizar una célula microbiana.
CN101434924A (zh) * 2008-12-17 2009-05-20 中南大学 一种分离严格厌氧产甲烷古菌的方法
CA3169782A1 (en) * 2009-08-27 2011-03-03 Pastoral Greenhouse Gas Research Ltd Complete genome sequence of the methanogen methanobrevibacter ruminantium
CN101864362B (zh) * 2010-05-19 2012-05-09 江苏加德绿色能源有限公司 一种复合微生物菌剂及其应用
DE102011119230B4 (de) * 2011-11-23 2013-07-11 Audi Ag Kraftwagen-Blinkleuchte und Verfahren zum Betreiben einer Blinkleuchte
US20160002672A1 (en) * 2012-12-21 2016-01-07 Danisco Us Inc. Production of isoprene, isoprenoid, and isoprenoid precursors using an alternative lower mevalonate pathway

Also Published As

Publication number Publication date
CN107129524A (zh) 2017-09-05
CN101932595A (zh) 2010-12-29
ES2587595T3 (es) 2016-10-25
MX2010003321A (es) 2010-08-03
JP2010539926A (ja) 2010-12-24
CA2700164A1 (en) 2009-04-02
DK2203466T3 (en) 2016-07-25
US20210332087A1 (en) 2021-10-28
AR068551A1 (es) 2009-11-18
WO2009041832A2 (en) 2009-04-02
WO2009041832A3 (en) 2009-06-11
DK2203467T3 (en) 2017-03-27
AU2014210649B2 (en) 2016-09-08
WO2009041831A9 (en) 2009-11-05
WO2009041830A2 (en) 2009-04-02
CA2700162C (en) 2018-08-14
ES2895908T3 (es) 2022-02-23
CA2700129C (en) 2021-07-20
US10995120B2 (en) 2021-05-04
UY31361A1 (es) 2009-04-30
RU2010116163A (ru) 2011-11-10
CL2008002860A1 (es) 2009-06-05
BRPI0817299A8 (pt) 2019-01-29
DK3327030T3 (da) 2021-10-04
JP5552053B2 (ja) 2014-07-16
US20100209998A1 (en) 2010-08-19
EP3936516A1 (en) 2022-01-12
EP2203467A4 (en) 2011-04-13
ZA201001933B (en) 2013-10-30
BR122021010737B1 (pt) 2021-09-21
US9296789B2 (en) 2016-03-29
US20170342112A1 (en) 2017-11-30
US8592556B2 (en) 2013-11-26
WO2009041832A9 (en) 2009-10-22
JP5558356B2 (ja) 2014-07-23
AU2008305846A1 (en) 2009-04-02
AU2008304018A1 (en) 2009-04-02
AR068553A1 (es) 2009-11-18
CN101918431B (zh) 2014-10-08
BRPI0817312B1 (pt) 2018-05-29
EP2203470A2 (en) 2010-07-07
US20100221185A1 (en) 2010-09-02
CA2700129A1 (en) 2009-04-02
US20100209999A1 (en) 2010-08-19
CL2008002861A1 (es) 2009-03-06
JP6067209B2 (ja) 2017-01-25
JP2010539928A (ja) 2010-12-24
EP2203467B1 (en) 2016-12-14
US10590170B2 (en) 2020-03-17
MX2010003319A (es) 2010-09-10
US20140220636A1 (en) 2014-08-07
CA2700164C (en) 2018-05-29
JP2015042166A (ja) 2015-03-05
ES2625144T3 (es) 2017-07-18
BR122020023381B1 (pt) 2021-09-08
US11926647B2 (en) 2024-03-12
UY31359A1 (es) 2009-04-30
CN101918431A (zh) 2010-12-15
EP2203466A2 (en) 2010-07-07
WO2009041831A1 (en) 2009-04-02
EP2203466B1 (en) 2016-04-06
CL2008002859A1 (es) 2009-03-06
CN102015755A (zh) 2011-04-13
AU2008304019A1 (en) 2009-04-02
WO2009041830A3 (en) 2009-07-02
US8586709B2 (en) 2013-11-19
BR122021010729B1 (pt) 2022-02-15
EP3327030A1 (en) 2018-05-30
JP2010539927A (ja) 2010-12-24
EP2203466A4 (en) 2011-04-13
MX340736B (es) 2016-07-22
JP2017046704A (ja) 2017-03-09
BRPI0817312A2 (pt) 2015-03-17
US20200325180A1 (en) 2020-10-15
UY31360A1 (es) 2009-04-30
MX2010003328A (es) 2010-08-16
CN101932595B (zh) 2016-02-10
RU2528854C2 (ru) 2014-09-20
AU2014210649A1 (en) 2014-09-04
EP2203470A4 (en) 2011-04-13
EP2203467A1 (en) 2010-07-07
CA2700162A1 (en) 2009-04-02
EP3327030B1 (en) 2021-07-21
WO2009041830A9 (en) 2009-08-27
NZ745324A (en) 2023-02-24
BRPI0817299A2 (pt) 2015-06-16
CN107129524B (zh) 2023-11-21

Similar Documents

Publication Publication Date Title
AR068552A1 (es) Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas
CL2015001353A1 (es) Molécula que contiene el dominio de fibronectina de tipo iii (fn3) biespecífico, donde el primer dominio se une al receptor del factor de crecimiento epidérmico (egrf) y el segundo al factor de crecimiento de hepatocitos (c-met); dominio de fn3; polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica que la comprende; y uso para tratar el cáncer.
DOP2015000039A (es) Inhibidores de glucosilceramida sintasa
CR20190319A (es) ANTICUERPOS CONTRA EL INHIBIDOR DEL ACTIVADOR DE PLASMINÓGENO TIPO 1 (PAI-1) Y USOS DE LOS MISMOS (Divisional 2016-0117)
CL2015001790A1 (es) Compuestos derivados de 3,4-dihidroisoquinolina sustituidos, inhibidores de prmt5; composicion farmaceutica; kit farmaceutico; metodo de inhibicion de prmt5; metodo para tratar la expresion de un gen; metodo para alterar la transcripcion; metodo de tratamiento de un trastorno tal como cancer, diabetes y obesisdad, entre otros.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
EA201290295A1 (ru) Специфичные к рецептору меланокортина-1 линейные пептиды
UY34643A (es) Derivados de 5-alquinilo piridina como inhibidores de apoptosis,composiciones farmacéuticas y sus usos como miméticos smac
AR077992A1 (es) Secuencia del genoma completo del metanogeno methanobrevibacter ruminantium
CO6761351A2 (es) Polipéptidos que se enlazan a cxcr2
DOP2013000209A (es) Inhibidores de glucosilceramida sintasa
MX2011011508A (es) Vector genico.
CL2008001047A1 (es) Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata.
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2011000957A1 (es) Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer.
CL2012002250A1 (es) Compuestos heterociclicos fusionados derivados de pirimidinonas, inhibidores potentes de cdc7; composicion farmaceutica; y su uso en la prevencion o el tratamiento del cancer.
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
IN2015DN03029A (es)
WO2011138328A3 (en) Use of inhibitory molecules for the treatment of pulmonary hypertension
BR112015021708A2 (pt) Inibidor de polipetídeo do tnfa, polinucleotídeo isolado, estrutura de expressão de ácido nucleico, célula de planta, composição farmacêutica e método de produção de um inibidor de polipeptídeo do tnfa
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
MX2014010698A (es) Polimeros cationicos con base en glucogeno.
BR112014024220A2 (pt) genes que codificam celulase

Legal Events

Date Code Title Description
FB Suspension of granting procedure